摘要
目的:探讨重组人干扰素α-2b凝胶阴道给药对宫颈病变人乳头瘤病毒(HPV)感染患者炎症因子及免疫功能的影响。方法:按随机数字表法将2021年1月-2022年12月我院收治的88例宫颈病变HPV感染患者分为两组。对照组(44例)予以聚甲酚磺醛治疗,观察组(44例)加用重组人干扰素α-2b(rhIFN α-2b)凝胶治疗,持续用药3个月。比较两组临床疗效、炎症因子水平、免疫功能及不良反应情况。结果:观察组治疗总有效率较对照组高,有统计学差异(P<0.05);观察组治疗后白介素-17(IL-17)及肿瘤坏死因子-α(TNF-α)水平低于对照组,CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)高于对照组,有统计学差异(P<0.05);两组不良反应相比,无统计学差异(P>0.05)。结论:rhIFN α-2b凝胶可增强宫颈病变HPV感染治疗效果,减轻宫颈部位炎症反应,促进机体免疫功能恢复正常,安全可靠,值得广泛应用。
Objective:To investigate the effect of recombinant human interferon α-2b gel vaginal administration on inflammatory factors and immune function in patients with cervical lesions infected with human papillomavirus(HPV).Method:88 patients with HPV infection in cervical lesions admitted to our hospital from January 2021 to December 2022 were divided into two groups using a random number table method.The control group(44 cases)was treated with polycarboxylate,while the observation group(44 cases)was treated with recombinant human interferon α-2b(rhIFN α-2b)gel treatment for 3 months.Compare the clinical efficacy,inflammatory factor levels,immune function,and adverse reactions between the two groups.Results:The total effective rate of treatment in the observation group was higher than that in the control group,with a statistical difference(P<0.05).After treatment,the levels of interleukin-17(IL-17)and tumor necrosis factor-α(TNF-α)in the observation group was significantly lower than the control group(P<0.05),meanwhile,the levels of CD3^(+),CD4^(+),CD4^(+)/CD8^(+) were significantly higher than the control group(P<0.05).There was no statistically significant difference about adverse reactions between the two groups(P>0.05).Conclusion:The rhIFN α-2b gel can enhance the therapeutic effect of HPV infection,reduce the inflammatory reaction,and accelerate the recovery of immune function in cervical lesions.It is safe and reliable,and is worth extensive application.
作者
张丽丽
彭丹
ZHANG Li-li;PENG Dan(Department of Obstetrics and Gynecology,the Second People’s Hospital of Nankang District of Ganzhou City,Ganzhou 341400,China;General Practice of The Third People’s Hospital of Yichun City,Yichun 336000,China)
出处
《宜春学院学报》
2023年第12期55-58,共4页
Journal of Yichun University
